The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...
The Foundation Fighting Blindness has allowed public open access to de-identified 4-year data from individuals participating ...
A new treatment is presented that eliminates the root cause of the disease and restores ocular surface health.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback